Unknown

Dataset Information

Human Papillomavirus T-Cell Cross-reactivity in Cervical Cancer: Implications for Immunotherapy Clinical Trial Design.


ABSTRACT:

Importance

Clinical trials are testing vaccines that target human papillomavirus 16 (HPV-16) oncoproteins for the treatment of cervical cancer regardless of the HPV type of the tumor. For patients with HPV-18-positive cancers, this strategy relies on cross-reactivity of HPV-16-reactive T cells against the HPV-18 oncoproteins.

Objectives

To determine the prevalence of HPV-16 and HPV-18 metastatic cervical cancers in women enrolling in clinical trials at a US medical center and to assess whether HPV oncoprotein-targeting tumor-infiltrating lymphocytes (TILs) and T-cell receptors (TCRs) possess HPV-16/HPV-18 oncoprotein cross-reactivity.

Design, setting, and participants

This study was conducted at the National Institutes of Health Clinical Center, a tertiary care resear

SUBMITTER: Helman SR 

PROVIDER: S-EPMC6324313 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature